To describe the direct costs related to warfarin/apixaban treatment
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
CHA2-DS2-VASc Score at Baseline
Timeframe: Baseline (from retrospective data retrieved in the study)
HAS-BLED Score at Baseline
Timeframe: Baseline (from retrospective data retrieved in the study)
CHA2-DS2-VASc Score at Month 6
Timeframe: Month 6 (from retrospective data retrieved in the study)
HAS-BLED Score at Month 6
Timeframe: Month 6 (from retrospective data retrieved in the study)
Percentage of Participants Categorized According to Number of Outpatient Visits During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Cost of Outpatient Visits During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Percentage of Participants Categorized According to Number of International Normalized Ratios (INR) Measurements During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Cost of INR Measurements During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Dosage of Warfarin and Apixaban at the Initiation of the Treatment
Timeframe: Baseline (from retrospective data retrieved in the study)
Dosage of Warfarin and Apixaban During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Cost of Medication During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Percentage of Participants Categorized According to Number of Hospital Admissions
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Cost of Hospital Admissions During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Percentage of Participants Categorized According to Number of Diagnostic Procedures
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Percentage of Participants Categorized According to Type of Ischemic Events During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Cost of Ischemic Events During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Percentage of Participants Categorized With Major Hemorrhagic Events During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Percentage of Participants Categorized According to Type of Minor Hemorrhagic Events During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Cost of Major Hemorrhagic Events During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Cost of Minor Hemorrhagic Events During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Number of Participants With Other Adverse Events During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Cost of Other Adverse Events During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)
Percentage of Participants Who Died (Treatment-Related) During First 6 Months of Treatment
Timeframe: Up to first 6 months of treatment (from retrospective data retrieved in the study)